poisar

Stocks · News reference

aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026

Benzinga Newsdesk

The planned Phase 3 trial will be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ATYR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading